| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10743793 | Maturitas | 2005 | 15 Pages |
Abstract
The clinical risk-benefit profile of raloxifene derived from the intermediate endpoints of this study suggests that it may be a better alternative to ccEPT for preventing long-term postmenopausal health risks in healthy postmenopausal women who are not suffering from vasomotor symptoms.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Patrick Neven, Deborah Quail, Fernando Marin, George Creatsas, Herman Depypere, Tomasz Rechberger, Soyi Liu-Léage, Imre Pavo, Henri Schmitt, Thomas Nickelsen,